Stefan Guhlke

Predictors of Long-Term Outcome in Patients with Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy with ¹⁷⁷Lu-Octreotate

Samer Ezziddin, Mared Attassi, Charlotte J. Yong‐Hing et al. · Journal of Nuclear Medicine · 2014 · 191 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

Long-Term Hematotoxicity After Peptide Receptor Radionuclide Therapy with ¹⁷⁷Lu-Octreotate

Amir Sabet, Khaled Ezziddin, Ulrich‐Frank Pape et al. · Journal of Nuclear Medicine · 2013 · 167 citations · Full text

Medicine, Nuclear Medicine, Radiation Oncology +17

Repeated Bone-Targeted Therapy for Hormone-Refractory Prostate Carcinoma: Randomized Phase II Trial With the New, High-Energy Radiopharmaceutical Rhenium-188 Hydroxyethylidenediphosphonate

H. Palmedo, Agnieska Manka-Waluch, Peter Albers et al. · Journal of Clinical Oncology · 2003 · 158 citations

Medicine, Nuclear Medicine, Oncology +16

Dose escalation study with rhenium-188 hydroxyethylidene diphosphonate in prostate cancer patients with osseous metastases

Holger Palmedo, Stefan Guhlke, Hans Bender et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2000 · 152 citations

Medicine, Oncology, Pharmacology +17

Detection of somatostatin receptor-positive tumours using the new 99m Tc-tricine-HYNIC- d -Phe 1 -Tyr 3 -octreotide: first results in patients and comparison with 111 In-DTPA- d -Phe 1 -octreotide

Michael Bangard, Stefan Guhlke, Hans Bender et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2000 · 116 citations

Medicine, Nuclear Medicine, Oncology +17